Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 200.79

-0.2%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: TI2, TechInvestorToo who wrote (24140)	8/7/1998 12:13:00 PM
From: Henry Niman	Read Replies (1) of 32384

I talked to IR this week. They said that the formula for profitability included ONTAK and topical Panretin approval coupled with either additional approvals (Targretin oral and topical) or milestone payments. ONTAK looks to be in good shape. It received a priority review and advisory board voted 14-0 for approval (for advanced CTCL). SRGN is ironing out final administrative issues and approval is expected this quarter followed by a launch next quarter. LGND is hiring a sales force, who are chomping at the bit. Topical Panretin has also been granted a priority review (for KS). FDA must say something by Nov. LGND not scheduled for Sept meeting, but will probably be reviewed in a special session (Nov?). Bear Stearns expects approval in Nov, but thinks that full scale launch could be delayed until 1Q of 99 because of holiday season. Later this year clinicals for Tragretin treatment of diabetes as well as Targretin or Panretin treatment of psoriasis should come out. I also expect some Phase II clinicals on one or more solid tumors. One or more deals should also be announced soon. I'm guessing that it will be for anti-androgens for BPH and male pattern baldness (could be two deals). I think that SERMs for Alzheimers is also a distinct possibility. IND for LGD1331 (anti-androgen) is expected for 1Q 99 (for prostate cancer). Fundamentals are moving forward nicely. I expect LGND to move up sharply from $10 as soon as a strong base is established. I suspect that oral Targretin will be next with an NDA filed at the end of this year or beginning of next. That would be followed by a NDA for topical Targretin (both for CTCL). Road show begins next month (Bear Stearns followed by BARS, & Oppenheimer). Later next year, an oral Panretin filing (for KS) is expected.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next